LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors
Back to library search

Enlightening The Jungle: The German Rules on Advertising Pharmaceuticals

August 2009AdvertisingPharmaceutical

Abstract

The legal rules applying to advertising medicines in Germany resemble a jungle. While a Medical Products Advertising Act (hereafter the Act) has been put in place, which concentrates on rules regarding advertising pharmaceuticals, the Act does not show the entire picture. It is surrounded and complemented by provisions embedded in other sources of law. Moreover, the legal structure of the Act is complex as the distinction between rules on advertising to professional parties and rules on marketing to end consumers is not clear in the face of the structure of the Act. Finally, provisions set out in the Act are of course subject to interpretation by competent courts, including both domestic ones and the European Court of Justice. Recently, courts have increasingly been making decisions which, have a significant impact upon how to construe and apply key rules and legal concepts of the Act. This essay strives to outline the chief categories in the light of pertinent case law, focussing on recent case law and taking both the Act and complementing other sources of law into account – thereby hopefully enlightening “the legal jungle” to some extent.

Subscribe to reador
PLS Logo Copyright & permissions

Author

Thorsten Witt

Corporate Counsel, Celesio, Germany

Related Papers

Supported Studies Quid Pro Quo
Many pharmaceutical companies (hereinafter Companies or Company) recognize the importance of supporting external studies and the role they play in fulfilling patients’ needs. High standard ethical research conducted by external...Read more
Portrait image of Ann Turi
Ann Turi
Senior Legal Counsel, Legal and Compliance R&D and Medical Legal Team, Gsk, USA
US and International Codes on Pharmaceutical Marketing Practices and Interaction with Healthcare Professionals - A Comparative Analysis and Outlook on Harmonization by FCPA Enforcement
In recent years, there has been an increasing focus on pharmaceutical marketing practices and interactions between pharmaceutical companies and healthcare professionals.  Concerns about real and perceived improprieties have led to...Read more
Portrait image of Roy Birnbaum
Roy Birnbaum
Counsel, Human Health International, Merck & Co, Inc., USA
Pharmaceutical Advertising in Denmark - Where did Freedom of Expression go?
Differences in the legal approach to advertisement of pharmaceuticals still exist within the European Union even though Directive 2001/83/EC of the European Parliament and of the Council of 6 November...Read more
Portrait image of Nicolai Ellehuus
Nicolai Ellehuus
Attorney-at-Law, Novo Nordisk Inc, USA
Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment
Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Kwanza Burney
Kwanza Burney
Compliance & Risk Professional | M.S.L. Candidate (Fordham Law), Fordham University School of Law, USA